Between Dec 19, 2024 and Jan 2, 2025, datasets can be submitted to DRUM but will not be processed until after the break. Staff will not be available to answer email during this period, and will not be able to provide DOIs until after Jan 2. If you are in need of a DOI during this period, consider Dryad or OpenICPSR. Submission responses to the UDC may also be delayed during this time.

Browsing by Subject "Frailty"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Understanding The Mechanisms Of Muscle Atrophy
    (2016-06) Liu, Haiming
    Skeletal muscle mass is regulated by protein turnover, the balance between protein synthesis and degradation. Muscle atrophy or a loss of muscle mass occurs when protein degradation exceeds protein synthesis, under conditions such as denervation and aging. Muscle atrophy is usually accompanied with reduced muscle contractility that lead to impaired physical activities and decreased quality of life. As a result, understanding the cellular and molecular mechanisms underlying the protein turnover is important to provide potential interventions and treatments for individuals suffered from muscle atrophy. In skeletal muscle the majority of the proteins are degraded by the ubiquitin-proteasome system (UPS). The core of this system is called proteasome, which works as a “garbage disposal” for the degradation of the myofibrillar proteins via specific enzymatic activities. The immunoproteasome, an inducible form of proteasome, also has a function of performing proteasome enzymatic activities primarily demonstrated in the immune system (generate peptides for antigen presentation). However, the role of the immunoproteasome during skeletal muscle protein degradation is unknown. Therefore, the purpose of the first study was to investigate the role of the standard and immuno-proteasome in denervation-induced protein degradation in skeletal muscle. In this study, wild type (WT) and the immunoproteasome deficient (lmp7-/-/mecl-1-/- double knockout, L7M1) mice were used to test the hypotheses that (1) the proteasome system is activated in denervation-induced muscle atrophy and (2) deletion of immunoproteasome subunits attenuates muscle atrophy by altering the proteasome composition and activities. Three major findings were found: following 7 and 14 days of denervation (1) an activation of the proteasome system occurs in conjunction with significant muscle atrophy in the WT mice; (2) the composition of the subunits within the 20S core appears to be influenced by deletion of the two immunoproteasome subunits; (3) however, the immunoproteasome was not essential for protein degradation induced by denervation. The purpose of the next study was to elucidate the physiological properties of skeletal muscle in response to denervation with a hypothesis that the UPS is a finely-tuned system that degrades myofibrillar proteins without impairing the contractility of the intact myosin and actin. We found an activation of the UPS accompanied with decreases in muscle size and force production post 14-day denervation. Importantly, the specific force and power were not impaired in the denervated muscles when compared to the controls. These results suggest that an activation of the UPS is associated with reductions in skeletal muscle quantity rather than quality. Frailty is a clinical syndrome, which is highly associated with sarcopenia, leads to adverse health outcomes, and increased mortalities. Animal models have the potential to tease out the cellular mechanisms underlying frailty. The purpose of the third study in this dissertation is to initiate the development of a Frailty Index in 27- to 28-month-old C57BL/6 mice that matches the established clinical frailty phenotype index in humans (weakness, slow walking speed, low activity level, poor endurance) 1. A frail or mildly-frail mouse was identified if presented ≥ three or two frailty criteria, respectively. From this study, we showed that one mouse was identified as frail and one was mildly-frail. This prevalence of 9% frailty is consistent with the prevalence of frailty in humans at the same survival age (11% frailty in human at age of 76-841). This work has been published in The Journals of Gerontology. Series A: Biological Sciences and Medical Sciences.